Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
De-extinction startup Colossal Biosciences is reportedly seeking new funding at a valuation between $20 billion and $30 billion. The company is diversifying its revenue through conservation technology, spin-off startups, and potential future biodiversity credits.
Why it matters
The massive valuation highlights growing investor interest in deep-tech, synthetic biology, and the commercialization of genetic research.
When de-extinction startup Colossal Biosciences revealed last year that it was attempting to “resurrect” the dire wolf from genetic material found in fossils , we argued that, despite the controversy surrounding the project, the company was building valuable technologies that justify its $10.2 billion valuation.
Now, roughly 16 months later, the startup is in talks to raise new funding at a $20 billion to $30 billion valuation, Axios reported .
It’s not clear who is leading the new round, or how much capital the five-year-old company is looking to raise. But we do know, according to the report, that Colossal has started generating revenue over the last year.
Colossal co-founder and CEO Ben Lamm told TechCrunch last year that the company sees three revenue streams for the business.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in